

# PACE/PAP/CRDP/SPBP1

## Provider Bulletin

March 24, 2023

### Commonwealth of Pennsylvania Drug Manufacturers' Rebate Program Non-Participating Manufacturers

#### REVISED

The Department of Aging has resolved the outstanding rebate issues with 3 of the manufacturers contained on the list distributed on February 16, 2023.

The remaining labelers identified below will no longer have their products reimbursed by PACE, PAP, and CRDP effective March 27, 2023.

Providers using products from these manufacturers may wish to explore alternative sources.

Labeler Number	Drug Manufacturer Name	Medication(s) Affected
15370	Carwin Pharmaceuticals	RyVent™
42494	Cameron Pharmaceuticals	hydrocortisone suppository
50261	Therapeutics MD	Imvexxy <sup>(R)</sup>
50474	UCB Inc	Neupro <sup>(R)</sup> , Keppra <sup>(R)</sup>
51285	TEVA Women's Health	Trexall <sup>(R)</sup>
51862	Mayne Pharmaceutical	fluorouracil, clonidine
54838	Lannett Company	haloperidol concentrate
59917	Adare Pharmaceuticals	potassium chloride
62175	Lannett Company	omeprazole, pantoprazole
68047	Larken Laboratories	Oscimin SL
68308	Mayne Pharma	Nystatin 100,000 unit/gm powder
68645	Legacy Pharmaceutical	hydrochlorothiazide, lisinopril
70594	Xellia Pharmaceuticals	vancomycin
71093	ACI Healthcare	gabapentin, metformin

**Effective March 31, 2023, GSK will no longer participate with the Commonwealth's Manufacturer Rebate Program as explained in the notification distributed on February 14, 2023. GSK medications will no longer be reimbursed by PACE, PAP, CRDP, or SPBP1.**

Labeler codes being terminated include: 00007, 00145, 00173

Below are **some** of the medications that will no longer be reimbursed:

00007	Coreg, Coreg CR
00145	Veltin, Brevoxyl, Clindets, Lacticare, Panoxyl, Sarna, Zeasorb
00173	Flovent, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta

Correspondence has been sent to prescribers that reimbursement will no longer be provided for GSK medications, and they may need to consider alternative therapies for their patients.

Please direct any questions concerning this non-compliance decision to the appropriate manufacturer.